Kali Therapeutics Enters into Agreement with Sanofi for Tri-specific T-cell Engager in Autoimmune Diseases
Monday, March 23, 2026
Kali Therapeutics has entered into an exclusive worldwide licensing agreement with Sanofi for its next-generation tri-specific T-cell engager, KT501, aimed at treating B cell-mediated autoimmune diseases.
Under the terms of the agreement, Sanofi will obtain global rights to develop and commercialise KT501, a novel tri-specific antibody developed using Kali Therapeutics’ proprietary research platform. The therapy is currently being evaluated in a first-in-human clinical study assessing its safety, tolerability, pharmacokinetics and pharmacodynamics in patients with rheumatoid arthritis.
Kali Therapeutics will receive upfront and near-term payments totalling $180 million. The company is also eligible for up to $1.05 billion in development and commercial milestone payments, along with tiered royalties on future product sales.
KT501 is designed to target a broad range of B cell populations while aiming to reduce cytokine release, which may improve safety outcomes. The programme utilises advanced protein engineering and CD3 masking technology to enhance therapeutic effectiveness while limiting potential toxicity.
The collaboration is expected to support the continued development of KT501 and accelerate its progress towards addressing unmet needs in autoimmune disease treatment.
Source: kalitherapeutics.com
